Phebra will handle approval and sales of Cumberland's Caldolor in Australia and New ZealandOctober 29th, 2009 Cumberland Pharma gets pain drug marketing partnerNEW YORK — Cumberland Pharmaceuticals Inc. said Thursday it found a marketing partner for its pain and fever drug Caldolor in Australia and New Zealand.
Arena Pharma reports new results on obesity drug candidate at conference, and shares advanceOctober 26th, 2009 more images
more imagesArena Pharma rises on new lorcaserin trial dataNEW YORK — Shares of Arena Pharmaceuticals Inc. traded higher Monday after the company reported new clinical trial data for its experimental obesity drug lorcaserin.
Corcept Therapeutics will sell stock and warrants to fund study and submission for CorluxOctober 13th, 2009 Corcept to raise $18M in sale of stock and optionsMENLO PARK, Calif. — Corcept Therapeutics Inc.
FDA says Pfizer's pill Selzentry appears safe for broader use against HIVOctober 6th, 2009 FDA sees no safety issues with Pfizer HIV drugWASHINGTON — The Food and Drug Administration said Tuesday an HIV drug from Pfizer appears safe for expanded use in patients who have not already taken other drugs to combat the virus. However, the FDA said Pfizer studies paint a mixed picture of its drug's effectiveness.
Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year highOctober 5th, 2009 Depomed says shingles pain drug meets study goalMENLO PARK, Calif. — Depomed Inc.
SciClone Pharma shares dive after company halts trial of RP101 for pancreatic cancerOctober 5th, 2009 SciClone tumbles after cancer drug trial stopsNEW YORK — Shares of SciClone Pharmaceuticals Inc. dropped Monday after the company suspended a study of its drug candidate RP101, which was intended as a treatment for late stage pancreatic cancer.
Oxidized form of vitamin A offers beneficial treatment for ulcerative colitisOctober 2nd, 2009 WASHINGTON - Retinoic acid-the oxidized form of vitamin A-may be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases, according to a new study. Published in the Journal of Leukocyte Biology, the study has specifically found that retinoic acid helps suppress out-of-control inflammation, a hallmark of active ulcerative colitis.
Antidepressant found to be just as effective as placebo in child pain reliefOctober 1st, 2009 WASHINGTON - A new study has shown that the antidepressant amitriptyline is just as effective as placebo in treating pain-predominant gastrointestinal disorders in children. "Many pharmaceutical products are prescribed for off-label use in children due to the lack of clinical trials testing the efficacy of the drugs in children and adolescents.
1.25 mn capsules of new swine flu drug enter Indian marketSeptember 25th, 2009 NEW DELHI - As swine flu cases continue to surge in the country, a pharma company Friday announced that it has pushed 1.25 million capsules of the drug to chemists across the country to combat the virus and it would be ready with 10 million such drugs by mid-October. We have launched Natflu capsules (generic version of Tamiflu - Oseltamivir), the first cure for swine flu to be available against medical prescription at designated chemists across India, said V.C.
Adolor buys rights to Eli Lilly drug, plans studies on opioid bowel dysfunctionSeptember 21st, 2009 Adolor buys rights to Eli Lilly drugEXTON, Pa. — Biotechnology company Adolor Corp.
GlaxoSmithKline, Xenoport report positive midstage study results from potential pain drugSeptember 17th, 2009 Glaxo, Xenoport report positive pain drug studyNEW YORK — GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study.
Dainippon Sumitomo Pharma of Japan acquiring US drug maker Sepracor for $2.6 billionSeptember 3rd, 2009 Dainippon of Japan acquires US drug maker SepracorTOKYO — Japanese drug company Dainippon Sumitomo Pharma Co. is acquiring U.S.
Analyst says MAP Pharma will rise when more details on migraine drug are reported next weekSeptember 2nd, 2009 Analyst says new Levadex data could lift MAP stockNEW YORK — MAP Pharmaceuticals Inc. plans to share additional data from testing of its migraine drug candidate Levadex next week, and a Wedbush Morgan analyst said the results could boost MAP's share price.
Acadia Pharmaceuticals shares plunge as Parkinson's disease drug fails late-stage studySeptember 1st, 2009 Acadia shares fall on failed Parkinson's studyNEW YORK — Shares of Acadia Pharmaceuticals Inc. plunged Tuesday after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson's disease psychosis.
Soluble fibre 'effective in treating irritable bowel syndrome'August 28th, 2009 LONDON - A new study by researchers from Utrecht University in the Netherlands has suggested that a soluble fibre supplement called psyllium should be the first line of attack in treating irritable bowel syndrome (IBS). In the study, researchers compared adding bran, psyllium and a dummy supplement to sufferers' diets.
